Abstract
IntroductionThe impact of disease-modifying agents on disease progression in Parkinson’s disease is largely assessed in clinical trials using clinical rating scales. These scales have drawbacks in terms of their ability...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have